Search Results
| Year | ID | Type | Category | Title | Authors |
|---|
| 2018 | CA04 | Poster | Complementary and Alternative Therapies |
Pilot Investigation of the Effects of Laughter Therapy on Mood, Stress, and Self-Efficacy in People with Multiple Sclerosis and Other Central Nervous System Disorders. |
Theodore R Brown, MD, MPH, MS Center at Evergreen Health, Evergreen Health, Kirkland WA, WA and Virginia I Simnad, MD, EvergreenHealth Multiple Sclerosis Center, EvergreenHealth, Kirkland, WA |
| 2018 | CA05 | Poster | Complementary and Alternative Therapies |
Intravenous Immunoglobulin As Adjunctive Therapy in Relapsing Remitting Multiple Sclerosis: A Novel Approach to Improving Quality of Life and Reducing Fatigue |
Lori Travis, MD, HonorHealth Neurology, Phoenix, AZ |
| 2018 | CA06 | Poster | Complementary and Alternative Therapies |
The Spirituality in the Quality of Life of Patients with Multiple Sclerosis |
| 2018 | CA07 | Poster | Complementary and Alternative Therapies |
Qigong for Multiple Sclerosis: A Pragmatic Randomized Feasibility Study |
Lita P Buttolph, PhD, Joshua Corn, ND, Douglas Hanes, PhD and Angela Senders, ND, MCR, Helfgott Research Institute, National University of Natural Medicine, Portland, OR |
| 2018 | CA08 | Poster | Complementary and Alternative Therapies |
The Functional Evolution of Patients with Multiple Sclerosis after the Use of Brazilian Herbal Medicine |
| 2018 | DX01 | Poster | Disease-Modifying Therapy |
Decision Factors Relating to Prescribing Disease-Modifying Therapies: Prediction of Adherence Behavior in Patients with Multiple Sclerosis |
Thomas Carattini, PharmD1, Emeline Bacque, PharmD1, Karl Wisseman, N/A2, Elizabeth Poole, PhD1, Lori Fafard, RN, BSN, CNRN, MSCN, CCRP2, Myassar Zarif, MD2, Marijean Buhse, NP-C, PhD2, Karen Blitz, DO2, Jared Srinivasan, N/A2, Carly Skudin, N/A3, Samy Zarif, N/A2, Barbara Bumstead, MS, ANCP, MSCN2, Lobat Hashemi, ScD1 and Mark Gudesblatt, MD2, (1)Sanofi, Cambridge, MA, (2)South Shore Neurologic Associates, Patchogue, NY, (3)Colgate University, Hamilton, NY |
| 2018 | DX02 | Poster | Disease-Modifying Therapy |
Decision Factors for Prescribing Disease-Modifying Therapies: Prediction of Intentional and Unintentional Low Adherence in Multiple Sclerosis Patients |
Thomas Carattini, PharmD1, Emeline Bacque, PharmD1, Karl Wisseman, N/A2, Elizabeth Poole, PhD1, Lori Fafard, RN, BSN, CNRN, MSCN, CCRP2, Myassar Zarif, MD2, Marijean Buhse, NP-C, PhD2, Karen Blitz, DO2, Jared Srinivasan, N/A2, Sean Tan, N/A2, Michael Zarif, N/A2, Haneet Chadha, N/A2, Barbara Bumstead, MS, ANCP, MSCN2, Lobat Hashemi, ScD1 and Mark Gudesblatt, MD2, (1)Sanofi, Cambridge, MA, (2)South Shore Neurologic Associates, Patchogue, NY |
| 2018 | DX03 | Poster | Disease-Modifying Therapy |
Selective S1PR1/S1PR5 Modulation Impacts Neurologic Architecture/Function By Improving Kinematic Gait and Protecting from Neuronal Breaks in a Demyelinating Mouse Model |
Kristen R. Taylor Meadows, PhD, Kevin C. Dines, PhD, Gregory J. Opiteck, PhD and Fiona L. Scott, PhD, Receptos, a wholly owned subsidiary of Celgene, San Diego, CA |
| 2018 | DX04 | Poster | Disease-Modifying Therapy |
17 Year Experience of Treating Multiple Sclerosis (MS) with Intramuscular Beta Interferon (INF)-1a Twice a Week (BIW) |
Robert W Baumhefner, MD, neurology, VA West Los Angeles MC, Los Angeles, CA |
| 2018 | DX05 | Poster | Disease-Modifying Therapy |
Analysis of Lymphocyte Counts and Infection Rates with Fingolimod in Patients with Primary Progressive Multiple Sclerosis over the Informs Trial |
Edward J. Fox, MD, PhD1, Fred Lublin, MD2, Jerry S Wolinsky, MD3, Jeffrey A Cohen, MD4, Xiangyi Meng, PhD5, Marina Ziehn, PhD5, Scott Kolodny, MD5, Norman Putzki, MD5 and Bruce AC Cree, MD, PhD6, (1)Central Texas Neurology Consultants, Round Rock, TX, (2)Icahn School of Medicine at Mount Sinai, New York, NY, (3)McGovern Medical School, UTHealth, Houston, TX, (4)Cleveland Clinic Foundation, Cleveland, OH, (5)Novartis Pharmaceuticals Corporation, East Hanover, NJ, (6)UCSF Neurology, Weill Institute for Neurosciences, San Francisco, CA |
| 2018 | DX06 | Poster | Disease-Modifying Therapy |
Efficacy of a Fourth Alemtuzumab Course in RRMS Patients with Disease Activity after Three Prior Courses: Analysis of Care-MS II |
Barry A Singer, MD1, Raed Alroughani, MD2, Aaron Boster, MD3, Ann D. Bass, MD4, Regina Berkovich, MD, PhD5, Giancarlo Comi, MD6, Oscar Fernandez, MD7, Ho Jin Kim, MD8, Volker Limmroth, MD, PhD9, Jan Lycke, MD10, Richard AL Macdonell, MD11, Basil Sharrack, MD, PhD12, Patrick Vermersch, MD13, Heinz Wiendl, MD14, Tjalf Ziemssen, MD, PhD15, Maria Melanson, MD, PhD16, Nadia Daizadeh, PhD16, Anthony Traboulsee, MD17 and on behalf of the CARE-MS II and CAMMS03409, Investigators18, (1)MS Center for Innovations in Care, Missouri Baptist Medical Center, St. Louis, MO, (2)Amiri Hospital, Sharq, Kuwait, (3)OhioHealth Neurological Physicians, Columbus, OH, (4)Neurology Center of San Antonio, San Antonio, TX, (5)University of Southern California, Keck School of Medicine, Los Angeles, CA, (6)University Vita-Salute San Raffaele, Milan, Italy, (7)Fundacion IMABIS, Hospital Universitario Carlos Haya, Malaga, Spain, (8)Research Institute and Hospital of National Cancer Center, Goyang, Korea, Republic of (South), (9)Klinik fur Neurologie und Palliativmedizin, Cologne, Germany, (10)Sahlgrenska University Hospital, Gothenburg, Sweden, (11)Austin Health and Florey Institute of Neuroscience and Mental Health, Melbourne, Victoria, Australia, (12)Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, United Kingdom, (13)University of Lille, Lille, France, (14)University of Munster, Munster, Germany, (15)Carl Gustav Carus University Hospital, Dresden, Germany, (16)Sanofi, Cambridge, MA, (17)University of British Columbia, Vancouver, BC, Canada, (18)on behalf of the CARE-MS II and CAMMS03409 Investigators, NJ |
| 2018 | DX07 | Poster | Disease-Modifying Therapy |
Durable Clinical Improvements with Alemtuzumab in RRMS Patients in the Absence of Continuous Treatment: 7-Year Follow-up of Care-MS II (TOPAZ Study) |
Barry A Singer, MD1, Raed Alroughani, MD2, Simon Broadley, MD3, Hans-Peter Hartung, MD4, Eva Kubala Havrdova, MD, PhD5, Ho Jin Kim, MD6, Celia Oreja-Guevara, MD7, Carlo Pozzilli, MD8, Patrick Vermersch, MD9, Sibyl Wray, MD10, Luke Chung, MD, MPH11, Nadia Daizadeh, PhD11, Madalina Chirieac, MD, MPH11, Krzysztof W Selmaj, MD12 and on behalf of the CARE-MS II, CAMMS03409, and TOPAZ, Investigators13, (1)MS Center for Innovations in Care, Missouri Baptist Medical Center, St. Louis, MO, (2)Amiri Hospital, Sharq, Kuwait, (3)School of Medicine, Gold Coast Campus, Griffith University, Queensland, Australia, (4)Department of Neurology, Medical Faculty, Heinrich-Heine University, Dusseldorf, Germany, (5)First Medical Faculty, Charles University in Prague, Prague, Czech Republic, (6)Research Institute and Hospital of National Cancer Center, Goyang, Korea, Republic of (South), (7)University Hospital San Carlos, Madrid, Spain, (8)Sapienza University of Rome, Rome, Italy, (9)University of Lille, Lille, France, (10)Hope Neurology MS Center, Knoxville, TN, (11)Sanofi, Cambridge, MA, (12)Medical University of Lodz, Lodz, Poland, (13)on behalf of the CARE-MS II, CAMMS03409, and TOPAZ Investigators, NJ |
| 2018 | DX08 | Poster | Disease-Modifying Therapy |
Real-World Disease Burden and Treatment Experiences of Patients with MS in the US: Results from the VsMS Survey |
Ann D. Bass, MD1, Bart Van Wijmeersch, MD, PhD2, Aaron Boster, MD3, Lori Mayer, DNP, MSN, RN, MSCN4, Mathias Maurer, MD5, Matt Mandel, MD6, Kersten Sharrock, MS6, Colin P Mitchell, PhD6 and Barry A Singer, MD7, (1)Neurology Center of San Antonio, San Antonio, TX, (2)Rehabilitation & MS-Centre Overpelt, BIOMED, Hasselt University, Hasselt, Belgium, (3)OhioHealth Neurological Physicians, Columbus, OH, (4)Central Texas Neurology Consultants, Round Rock, TX, (5)Klinikum Wurzburg Mitte gGmbH, Wurzburg, Germany, (6)Sanofi, Cambridge, MA, (7)MS Center for Innovations in Care, Missouri Baptist Medical Center, St. Louis, MO |
| 2018 | DX09 | Poster | Disease-Modifying Therapy |
A Single-Center Review Of Therapies Used Prior To Alemtuzumab In Patients With Multiple Sclerosis |
Suma Shah, MD1, Anastasie Dunn-Pirio, MD, MS1, Jenelle M. Hall, PharmD2, Bryan Walker, PA-C1, Nick Hudak, PA-C1, Fletcher Hartsell, MD1, Mark Skeen, MD1 and Christopher Eckstein, MD1, (1)Neurology, Duke University, Durham, NC, (2)Duke University Health System, Durham, NC |
| 2018 | DX10 | Poster | Disease-Modifying Therapy |
Effects of Cladribine Tablets on MRI Outcomes in High Disease Activity (HDA) Patients with Relapsing Multiple Sclerosis (RMS) in the CLARITY Study |
Gavin Giovannoni, MBBCh, PhD, FCP (Neurol., SA), FRCP, FRCPath, Queen Mary University London, Blizard Institute, Barts and the London School of Medicine and Dentistry, London, United Kingdom, Kottil Rammohan, MD, Ohio State University Hospital, Columbus, OH, Stuart Cook, MD, Rutgers, The State University of New Jersey, New Jersey Medical School, Newark, NJ, Giancarlo Comi, MD, Vita-Salute San Raffaele University, Milan, Italy, Peter Rieckmann, MD, Akademisches Krankenhaus Sozialstiftung Bamberg, Bamberg, Germany, Per Soelberg Soerensen, MD, Department of Neurology, University of Copenhagen, Copenhagen, Denmark, Patrick Vermersch, MD, University of Lille, Lille, France, Fernando Dangond, MD, EMD Serono, Inc., Billerica, MA and Christine Hicking, MS, Merck KGaA, Darmstadt, Germany |
| 2018 | DX11 | Poster | Disease-Modifying Therapy |
A Post Hoc Analysis of No Evidence of Disease Activity (NEDA) in Patients with Highly Active RMS Who Were Treated with Cladribine Tablets in CLARITY |
Gavin Giovannoni, MBBCh, PhD, FCP (Neurol., SA), FRCP, FRCPath, Queen Mary University London, Blizard Institute, Barts and the London School of Medicine and Dentistry, London, United Kingdom, Kottil Rammohan, MD, Ohio State University Hospital, Columbus, OH, Stuart Cook, MD, Rutgers, The State University of New Jersey, New Jersey Medical School, Newark, NJ, Giancarlo Comi, MD, Vita-Salute San Raffaele University, Milan, Italy, Peter Rieckmann, MD, Akademisches Krankenhaus Sozialstiftung Bamberg, Bamberg, Germany, Per Soelberg Soerensen, MD, Department of Neurology, University of Copenhagen, Copenhagen, Denmark, Patrick Vermersch, MD, University of Lille, Lille, France, Fernando Dangond, MD, EMD Serono, Inc., Billerica, MA and Christine Hicking, MS, Merck KGaA, Darmstadt, Germany |
| 2018 | DX12 | Poster | Disease-Modifying Therapy |
Number-Needed-to-Treat Analyses Comparing Clinical Disease Outcomes and Disability Improvement in RMS Patients Treated with Alemtuzumab or Ocrelizumab |
Aaron Boster, MD1, Bart Van Wijmeersch, MD, PhD2, Raed Alroughani, MD3, Giancarlo Comi, MD4, Regina Berkovich, MD, PhD5, Guillermo Izquierdo, MD6, Daniel Kantor, MD7, Christopher LaGanke, MD8, Volker Limmroth, MD, PhD9, Richard AL Macdonell, MD10, Heinz Wiendl, MD11, Maria Melanson, MD, PhD12, Karthinathan Thangavelu, PhD12, Mark S Freedman, MD13 and on behalf of the CAMMS223, CARE-MS I, and CARE-MS II, Investigators14, (1)OhioHealth Neurological Physicians, Columbus, OH, (2)Rehabilitation & MS-Centre Overpelt, BIOMED, Hasselt University, Hasselt, Belgium, (3)Amiri Hospital, Sharq, Kuwait, (4)University Vita-Salute San Raffaele, Milan, Italy, (5)University of Southern California, Keck School of Medicine, Los Angeles, CA, (6)Virgen Macarena University Hospital, Seville, Spain, (7)Florida Atlantic University, Boca Raton, FL, (8)North Central Neurology Associates, Cullman, AL, (9)Klinik fur Neurologie und Palliativmedizin, Cologne, Germany, (10)Austin Health and Florey Institute of Neuroscience and Mental Health, Melbourne, Victoria, Australia, (11)University of Munster, Munster, Germany, (12)Sanofi, Cambridge, MA, (13)University of Ottawa and the Ottawa Hospital Research Institute, Ottawa, ON, Canada, (14)on behalf of the CAMMS223, CARE-MS I, and CARE-MS II Investigators, NA, NJ |
| 2018 | DX13 | Poster | Disease-Modifying Therapy |
The 20-Year History: Change of Multiple Sclerosis Patient Profile over 20 Years |
Serkan Ozakbas, Professor Of Neurology, Department of Neurology, Dokuz Eylul University, Izmir, Turkey, Bilge Piri Cinar, MD, Bulent Ecevit University, Zonguldak, Turkey, Turhan Kahraman, Phd, Katip Celebi University, Izmir, Turkey and Gorkem Kosehasanogullari, MD, Usak State Hospital, Usak, Turkey |
| 2018 | DX14 | Poster | Disease-Modifying Therapy |
Alemtuzumab Use Among Narcoms Registry Participants |
Amber Salter, PhD1, Tuula Tyry, PhD2, Robert J Fox, MD3, Ruth Ann Marrie, MD, PhD4, Lobat Hashemi, ScD5, Kathryn Munoz, MPH, PhD5, Thomas Carattini, PharmD5, Alden Smith, PharmD5 and Gary Cutter, PhD6, (1)Washington University in St Louis, St Louis, MO, (2)Dignity Health, St. Joseph’s Hospital and Medical Center, Phoenix, AZ, (3)Cleveland Clinic, Cleveland, OH, (4)University of Manitoba, Winnipeg, MB, Canada, (5)Sanofi, Cambridge, MA, (6)University of Alabama at Birmingham, Birmingham, AL |
| 2018 | DX15 | Poster | Disease-Modifying Therapy |
Teriflunomide Use in Participants with Relapsing-Remitting MS Enrolled in the NARCOMS Registry |
Amber Salter, PhD1, Tuula Tyry, PhD2, Samantha Lancia, MS1, Robert J Fox, MD3, Ruth Ann Marrie, MD, PhD4, Lobat Hashemi, ScD5, Kathryn Munoz, MPH, PhD5, Thomas Carattini, PharmD, MBA5, Alden Smith, PharmD5 and Gary Cutter, PhD6, (1)Washington University in St Louis, St Louis, MO, (2)Dignity Health, St. Joseph’s Hospital and Medical Center, Phoenix, AZ, (3)Cleveland Clinic, Cleveland, OH, (4)University of Manitoba, Winnipeg, MB, Canada, (5)Sanofi, Cambridge, MA, (6)University of Alabama at Birmingham, Birmingham, AL |
| 2018 | DX16 | Poster | Disease-Modifying Therapy |
Treatment Retention and Satisfaction in Patients Randomized to Fingolimod or Injectable Disease-Modifying Therapies in PREFERMS: Effect of Previous Treatment |
Florian P Thomas, MD, PhD, MA1,2, Samuel F Hunter, MD3, Xiangyi Meng, PhD4, Lesley Schofield, PhD4, Scott Kolodny, MD4, Nadia Tenenbaum, MD4 and Bruce AC Cree, MD, PhD5, (1)Neurology, Hackensack University Medical Center, Hackensack, NJ, (2)Seton Hall-Hackensack Meridian School of Medicine, South Orange, NJ, (3)Advanced Neurosciences Institute, Franklin, TN, (4)Novartis Pharmaceuticals Corporation, East Hanover, NJ, (5)UCSF Neurology, Weill Institute for Neurosciences, San Francisco, CA |
| 2018 | DX17 | Poster | Disease-Modifying Therapy |
Early Impact of Expanding Generic Glatiramer Acetate Options Confined to Payer-Driven Conversion/Competition within Glatiramer Acetate Class |
Virginia R Schobel, MSc, Neurology Market Intelligence, Spherix Global Insights, Exton, PA and Jennifer Robinson, BS, President, Spherix Global Insights, Exton, PA |
| 2018 | DX18 | Poster | Disease-Modifying Therapy |
Early Uptake Analysis of Ocrelizumab Highlights Shifting and Distinct Treatment Paradigms By Multiple Sclerosis Subtypes |
Virginia R Schobel, MSc, Neurology Market Intelligence, Spherix Global Insights, Exton, PA and Jennifer Robinson, BS, President, Spherix Global Insights, Exton, PA |
| 2018 | DX19 | Poster | Disease-Modifying Therapy |
Real World Data Highlights Impact of Ocrelizumab Availability on Recently Switched Multiple Sclerosis Patient Characteristics and Switching Patterns |
Virginia R Schobel, MSc, Neurology Market Intelligence, Spherix Global Insights, Exton, PA and Jennifer Robinson, BS, President, Spherix Global Insights, Exton, PA |
| 2018 | DX20 | Poster | Disease-Modifying Therapy |
Long-Term Predictors of Clinical Outcomes in Patients with Multiple Sclerosis in the Phase 3 FREEDOMS, FREEDOMS II and TRANSFORMS Studies |
Till Sprenger, MD1,2, Aaron Boster, MD3, Xiangyi Meng, PhD4, Shannon Ritter, MS4, Daniela Piani Meier, PhD5, Davorka Tomic, PhD5, Diego Silva, MD, PhD5, Frederik Barkhof, MD, PhD6,7 and Pavle Repovic, MD, PhD8, (1)Department of Neurology, DKD HELIOS Klinik, Wiesbaden, Germany, (2)Medical Image Analysis Center, University Hospital Basel, Basel, Switzerland, (3)OhioHealth Neurological Physicians, Columbus, OH, (4)Novartis Pharmaceuticals Corporation, East Hanover, NJ, (5)Novartis Pharma AG, Basel, Switzerland, (6)Department of Radiology and Nuclear Medicine, VU University Medical Center, Amsterdam, Netherlands, (7)Institutes of Neurology and Healthcare Engineering, University College London, London, United Kingdom, (8)Multiple Sclerosis Center, Swedish Neuroscience Institute, Seattle, WA |
| 2018 | DX21 | Poster | Disease-Modifying Therapy |
Current Correlations between Disease Modifiers & Physiologic Measurements from the MS MOSAIC Study |
Fletcher L Hartsell III, MD MPH, Neurology, Duke University School of Medicine, Durham, NC |
| 2018 | DX22 | Poster | Disease-Modifying Therapy |
Acapella: Real World Experience with Ocrelizumab: An Observational Study Evaluating Safety in Patients with Relapsing and Progressive MS |
Kelly F Luciani, B.S., Joshua D Katz, M.D., Ellen S Lathi, M.D. and Hannah M Geils, B.S., The Elliot Lewis Center for Multiple Sclerosis Care, Wellesley, MA |
| 2018 | DX23 | Poster | Disease-Modifying Therapy |
The Importance of the Role of a Patient Safety Coordinator in a Comprehensive Multiple Sclerosis Center. |
Vineet Nadkarni, BS, Tirisham V Gyang, MD, Lindsay Falk, ARNP and Augusto Miravalle, MD, Neurology, University of Florida, Gainesville, FL |
| 2018 | DX24 | Poster | Disease-Modifying Therapy |
Evaluation of Multiple Sclerosis Patients’ Disease Modifying Therapy Prior to and after Disease Relapse |
Sharon R Tingen, PharmD, BCPS, Neurology, University of Virginia, Charlottesville, VA, Myla D Goldman, MD, Msc, University of Virginia, Charlottesville, VA and Robert D’Eramo, PharmD, Pharmacy, University of Virginia, Charlottesville, VA |
| 2018 | DX25 | Poster | Disease-Modifying Therapy |
A Trial of Prednisone and Acetaminophen Versus Acetaminophen Alone in Minimizing Flu-like Symptoms from Pegylated Interferon Beta-1a |
Anthony M Iuso, BS, Clinical Research, Holy Name Medical Center, Teaneck, NJ, Mary Ann Picone, MD, Holy Name Medical Center, Teaneck, NJ and Karen Blitz, DO, South Shore Neurologic Associates, Patchogue, NY |
| 2018 | DX26 | Poster | Disease-Modifying Therapy |
Effect of Montelukast on GI Tolerability in Patients with Relapsing-Remitting Multiple Sclerosis Receiving Delayed-Release Dimethyl Fumarate: MITIGATE Study Results |
Carlo Tornatore, MD1, Teri Schreiner, MD MPH2, Kyle E Smoot, MD3, Natasha Frost, M.D.4, Oksana Mokliatchouk, PhD5, Christophe Hotermans, MD5 and Irene Koulinska, MD, ScD5, (1)Department of Neurology, Medstar Georgetown University Hospital, Washington, DC, (2)Neurology, Children’s Hospital Colorado, Aurora, CO, (3)Providence Multiple Sclerosis Center, Portland, OR, (4)Neurology, School of Medicine and Public Health, University of Wisconsin, Madison, WI, (5)Biogen, Cambridge, MA |
| 2018 | DX27 | Poster | Disease-Modifying Therapy |
Pregnancy Outcomes with Ozanimod: Data from the Clinical Development Program |
Denise Campagnolo, MD1, Catherine Montero-Embalsado, BS2, Susan Meier-Davis, DVM, PhD, DABT2 and Neil Minton, MD2, (1)Celgene Corporation, Summit, NJ, (2)Receptos, a wholly owned subsidiary of Celgene, San Diego, CA |
| 2018 | DX28 | Poster | Disease-Modifying Therapy |
Patients’ Preferences and Willingness-to-Pay for Disease-Modifying Therapies: A Discrete Choice Experiment in the U.S. |
Surachat Ngorsuraches, Ph.D.1, Natasha Frost, M.D.2, Jerome Freeman, M.D., F.A.C.P.3, Diana Brixner, R.Ph., Ph.D., FAMCP4, Jane Mort, Pharm.D.1 and James Clem, Pharm.D.1, (1)Pharmacy Practice, College of Pharmacy and Allied Health Professions, South Dakota State University, Brookings, SD, (2)Neurology, School of Medicine and Public Health, University of Wisconsin, Madison, WI, (3)Neurosciences, Sanford School of Medicine, University of South Dakota, Sioux Falls, SD, (4)Pharmacotherapy, College of Pharmacy, University of Utah, Salt Lake City, UT |
| 2018 | DX29 | Poster | Disease-Modifying Therapy |
Pain in Multiple Sclerosis, Is Dimethyl Fumarate Associated to Less Pain, When Compared to Other Disease Modifying Therapies? |
Amputch Karukote, MD1, Volker Neugebauer, MD, PHD2 and Mirla Avila, MD1, (1)Neurology, Texas Tech University Health Sciences Center, Lubbock, TX, (2)Pharmacology and Neuroscience, Texas Tech University Health Sciences Center, Lubbock, TX |
| 2018 | DX30 | Poster | Disease-Modifying Therapy |
Simultaneous Use of Immunoglobulin with Natalizumab Attenuates the JCV Stratify Index Elevation- a 2 Year Analysis |
Ronald Bailey, M.D.1, Marco Pasco, MPH1, Taif Kaissi, M.D.1, Shard Yaqoot, R.N.2, Bhavesh Desai, D. Pharm, J.D.2 and Maria Aziz, A.S.1, (1)Neurology, The Neurology Group, Pomona, CA, (2)Pharmacy, CA Specialty Pharmacy, Whittier, CA |
| 2018 | DX31 | Poster | Disease-Modifying Therapy |
Stevens-Johnson Syndrome Associated with Daclizumab Use- Report of Two Cases |
Ronald Bailey, M.D.1, Marco Pasco, MPH1 and Shard Yaqoot, R.N.2, (1)Neurology, The Neurology Group, Pomona, CA, (2)Pharmacy, CA Specialty Pharmacy, Whittier, CA |
| 2018 | DX32 | Poster | Disease-Modifying Therapy |
BELTRIMS: Belgian Treatment Registry in MS |
Barbara Willekens, MD, Neurology, Antwerp University Hospital, Edegem, Belgium, Vincent Van Pesch, MD, PhD, Neurology, Cliniques Universitaires Saint-Luc, Brussels, Belgium, Souraya El Sankari, MD, PhD, Neurology, Cliniques Universitaires St-Luc, Brussels, Belgium, Benedicte Dubois, PhD/MD, Laboratory for Neuroimmunology, Department of Neurosciences, KU Leuven, Leuven, Belgium, Marie D’Hooghe, MD, PhD, Neurology, National MS Center, Melsbroek, Belgium, Guy Nagels, MD, PhD, Neurology, National Multiple Sclerosis Center, Melsbroek, Belgium, Daniel Guillaume, MD, PhD, neurology, Centre neurologique et de readaption fonctionelle de Fraiture-en-Condroz, Fraiture-en-Condroz, Belgium, Pierrette Seeldrayers, MD, PhD, Neurology, Centre Hospitalier Universitaire Charleroi, Charleroi, Belgium and On behalf of the Belgian Study Group for Multiple Sclerosis, -, BSGMS, Brussels, Belgium |
| 2018 | DX33 | Poster | Disease-Modifying Therapy |
Patient Perspectives on Factors Related to Medication Persistence in MS Patients Experiencing DMF-Associated Gastrointestinal Events |
Barry Hendin, M.D.1, Lori Mayer, DNP, MSN, RN, MSCN2, Marie Namey, APRN, MSCN3, Michael R Edwards, PhD4, Beth Jordan, MBA4, Leslie Beth Herbert, PhD5 and Irene Koulinska, MD, ScD4, (1)Phoenix Neurological Associates, Phoenix, AZ, (2)Central Texas Neurology Consultants, Round Rock, TX, (3)Cleveland Clinic, Cleveland, OH, (4)Biogen, Cambridge, MA, (5)Health Union, LLC, Philadelphia, PA |
| 2018 | DX34 | Poster | Disease-Modifying Therapy |
Using Autologous Transplantation of Mesenchymal STEM CELLS for Patients with Multiple Sclerosis |
Aliaksei Barysau Sr., MD, Department of Neurology and Neurosurgery, Belarusian state medical university, Minsk, Belarus |
| 2018 | DX35 | Poster | Disease-Modifying Therapy |
Long-Term Follow up of Treatment with Interferon Beta 1-b in a Cohort of 87 Patients with Multiple Sclerosis: A 23-Year Observational Study in a Single Center |
Mirela Cerghet, MD, PhD1, Ahmad M Siddiqi, MD2, Lonni Schultz, PhD3, Helena Bulka, DO1, Carol Freeman, BSci, NP4 and Stanton Elias, MD1, (1)Neurology, Henry Ford Hospital, Detroit, MI, (2)Neurology, Henry Ford Health System, detroit, MI, (3)Public Health Science, Henry Ford Health System, Detroit, MI, (4)Neurology, Henry Ford Health System, Detroit, MI |